ELIZABETH MITTENDORF, M.D.
Radiology at Holcombe Blvd, Houston, TX

License number
Texas M1941
Category
Radiology
Type
Surgical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991

Personal information

See more information about ELIZABETH MITTENDORF at radaris.com
Name
Address
Phone
Elizabeth A. Mittendorf
Houston, TX
(713) 664-2886
Elizabeth A Mittendorf, age 53
5151 Edloe St, Houston, TX 77005
Elizabeth A Mittendorf
429 Milby St, Houston, TX 77003
(713) 664-2886

Organization information

See more information about ELIZABETH MITTENDORF at bizstanding.com

Elizabeth Mittendorf MD

1515 Holcombe Blvd, Houston, TX 77030

Industry:
Surgeons
Phone:
(713) 792-6161 (Phone)
Elizabeth Ann Mittendorf


Elizabeth A Mittendorf MD

1400 Pressler St, Houston, TX 77030

Categories:
Physicians & Surgeons
Phone:
(713) 745-4516 (Phone)

Professional information

See more information about ELIZABETH MITTENDORF at trustoria.com
Elizabeth Mittendorf Photo 1
Dr. Elizabeth Mittendorf, Houston TX - MD (Doctor of Medicine)

Dr. Elizabeth Mittendorf, Houston TX - MD (Doctor of Medicine)

Specialties:
General Surgery
Address:
1515 Holcombe Blvd SUITE 444, Houston 77030
(713) 792-6161 (Phone), (800) 392-1611 (Fax)
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
SURGICAL ONCOLOGY
1400 Pressler St SUITE F, Houston 77030
(713) 792-6940 (Phone), (713) 745-5068 (Fax)
1400 Pressler St, Houston 77030
Procedures:
Biopsy of Breast, Excision of Breast Tumor, Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer, Lymph Node Biopsy or Excision, Mastectomy, Removal or Destruction of Rectal or Intestinal Tumor (incl. Colonoscopy, Proctosigmoidoscopy, Sigmoidoscopy & Control of Hemorrhage)
Conditions:
Breast Cancer, Breast Lump/Mass, Carcinoma in Situ, Hemorrhoids, Lipomas, Peripheral Vascular Disease (PAD, PVD), Secondary Malignancies
Certifications:
General Surgery, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1515 Holcombe Blvd SUITE 444, Houston 77030
1400 Pressler St, Houston 77030
SURGICAL ONCOLOGY
1400 Pressler St SUITE F, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical School
Case Western Reserve University School of Medicine
Graduated: 1996
Cwru University Hospital
Graduated: 1997


Elizabeth Ann Mittendorf Photo 2
Elizabeth Ann Mittendorf, Houston TX

Elizabeth Ann Mittendorf, Houston TX

Specialties:
Surgeon
Address:
1515 Holcombe Blvd, Houston, TX 77030
Board certifications:
American Board of Surgery Certification in Surgery


Elizabeth Ann Mittendorf Photo 3
Elizabeth Ann Mittendorf, Houston TX

Elizabeth Ann Mittendorf, Houston TX

Specialties:
Surgery, Surgical Oncology
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
Education:
Case Western Reserve University(1996)


Elizabeth Mittendorf Photo 4
Low Molecular Weight Cyclin E (Lmw-E) As A Biomarker For Personalization Of Cancer Therapies

Low Molecular Weight Cyclin E (Lmw-E) As A Biomarker For Personalization Of Cancer Therapies

US Patent:
2012011, May 10, 2012
Filed:
Mar 10, 2010
Appl. No.:
13/255380
Inventors:
Khandan Keyomarsi - Houston TX, US
Nikki Delk - Houston TX, US
Kelly K. Hunt - Houston TX, US
Hannah Wingate - Humble TX, US
Elizabeth A. Mittendorf - Houston TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
Research Development Foundation - Carson City NV
International Classification:
A61K 39/395, A61P 35/00, A61K 31/566, A61K 31/553, G01N 33/577, A61K 31/4196
US Classification:
4241331, 435 723, 514383, 514177, 51421108
Abstract:
Methods are disclosed for predicting a patient response to anti-Her2 therapy or anti-aromatase therapy. In certain embodiments, the methods involve the identification of low molecular weight cyclin E (LMW-E) in cancers, such as breast cancer cells, as a predictive and prognostic marker. In further embodiments, LMW-E expression by a cancerous or pre-cancerous cell may be used to predict response to an aromatase inhibitor and/or CDK2 inhibitor, and determination of LMW-E expression may be used in the personalization of cancer therapies.